Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

The U.S. Food and Drug Administration (FDA) has escalated its regulatory dispute with Amgen over the autoimmune drug Tavneos, accusing the company of manipulating clinical trial data and moving toward potential market withdrawal. The case, centered on alleged data integrity
A recent industry analysis highlights that many pharmaceutical manufacturing sites still fail EU GMP Annex 1 inspections despite passing traditional GMP audits. Published on 15 May 2026 by industry analyst Dobrin Kolarov, the report shows that regulators now prioritize real-time
Japan’s FY26 National Health Insurance (NHI) drug price revision has taken effect following analysis by GlobalData released on May 8, 2026. The policy cuts prices across nearly 15,800 medicines by an average of 4.02% and expands the G1 repricing system.
A senior leadership change is unfolding inside the U.S. Food and Drug Administration as Tracy Beth Hoeg, acting head of the agency’s drug evaluation center, is expected to leave after the resignation of FDA Commissioner Marty Makary in Washington, according
The U.S. Food and Drug Administration issued a warning letter to Simtra Biopharma Solutions after an inspection revealed significant contamination-related GMP violations at its sterile manufacturing facility in Halle, Germany. Inspectors identified repeated microbial recoveries, aseptic processing failures, and weak
The U.S. Food and Drug Administration launches a new drug repurposing initiative to address unmet medical needs in chronic and rare diseases. The agency invites public input on approved medicines that may support new indications using existing scientific evidence. Additionally,
At INTERPHEX 2026 in New York, George Kwiecinski, CEO and co-founder of Global Key Solutions Corp, discussed how AI reshapes FDA regulatory compliance and GMP inspection strategy in an interview with PharmTech. He explained that limited inspection capacity, evolving QMSR
FDA escalates enforcement in 2026 and exposes major GMP failures across India, China, and the US. The agency identifies repeated breakdowns in OOS investigations, data integrity controls, and quality oversight systems. At the same time, FDA also challenges Intas Pharmaceuticals,
A recent analysis by Megha Sinha of Kamet Consulting Group highlights post-approval life cycle change management as one of the most critical yet underdeveloped areas in pharmaceutical operations. With increasing regulatory complexity, global site transfers, and rising change volumes across
Pharmaceutical manufacturing is undergoing a major structural shift as companies like GSK, Bristol Myers Squibb, and Sanofi sell production facilities to CDMOs. Reported in May 2026, this wave of asset transfers reflects rising GMP compliance costs, onshoring pressure, and demand